Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roman Gulati

Showing results (11-20 of 154) with videos related to

Pageof 16
Sort By:
The Journal of Urology|September 6, 2022
Editorial CommentRoman Gulati, Yaw A Nyame
Cancer|December 2, 2016
Insights from the PLCO trial about prostate cancer screeningRoman Gulati, Peter C Albertsen
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 27, 2022
Stage Shift as an Endpoint in Cancer Screening Trials: Implications for Evaluating Multicancer Early Detection TestsLukas Owens, Roman Gulati, Ruth Etzioni
Histopathology|May 5, 2017
Stalk versus base invasion in pT1 papillary cancers of the bladder: improved substaging system predicting the risk of progressionMargaret Lawless, Roman Gulati, Maria Tretiakova
Annals of Internal Medicine|April 21, 2018
Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO TrialsAlex Tsodikov, Roman Gulati, Ruth Etzioni
Biometrics|May 16, 2007
Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trendsDonatello Telesca, Ruth Etzioni, Roman Gulati
Journal of the National Cancer Institute|August 27, 2021
Multicancer Early Detection: Learning From the Past to Meet the FutureRuth Etzioni, Roman Gulati, Noel S Weiss
American Journal of Preventive Medicine|May 10, 2021
When to Discuss Prostate Cancer Screening With Average-Risk MenRoman Gulati, Sigrid V Carlsson, Ruth Etzioni
Annals of Internal Medicine|February 6, 2013
Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harmsRoman Gulati, John L Gore, Ruth Etzioni
Urologic Oncology|March 28, 2015
Measures of survival benefit in cancer drug development and their limitationsRuth Etzioni, Roman Gulati, Daniel W Lin
Pageof 16

Showing results (11-20 of 154) with videos related to

Sort By:
Pageof 16
The Journal of Urology|September 6, 2022
Editorial CommentRoman Gulati, Yaw A Nyame
Cancer|December 2, 2016
Insights from the PLCO trial about prostate cancer screeningRoman Gulati, Peter C Albertsen
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 27, 2022
Stage Shift as an Endpoint in Cancer Screening Trials: Implications for Evaluating Multicancer Early Detection TestsLukas Owens, Roman Gulati, Ruth Etzioni
Histopathology|May 5, 2017
Stalk versus base invasion in pT1 papillary cancers of the bladder: improved substaging system predicting the risk of progressionMargaret Lawless, Roman Gulati, Maria Tretiakova
Annals of Internal Medicine|April 21, 2018
Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO TrialsAlex Tsodikov, Roman Gulati, Ruth Etzioni
Biometrics|May 16, 2007
Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trendsDonatello Telesca, Ruth Etzioni, Roman Gulati
Journal of the National Cancer Institute|August 27, 2021
Multicancer Early Detection: Learning From the Past to Meet the FutureRuth Etzioni, Roman Gulati, Noel S Weiss
American Journal of Preventive Medicine|May 10, 2021
When to Discuss Prostate Cancer Screening With Average-Risk MenRoman Gulati, Sigrid V Carlsson, Ruth Etzioni
Annals of Internal Medicine|February 6, 2013
Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harmsRoman Gulati, John L Gore, Ruth Etzioni
Urologic Oncology|March 28, 2015
Measures of survival benefit in cancer drug development and their limitationsRuth Etzioni, Roman Gulati, Daniel W Lin
Pageof 16